BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 14735184)

  • 81. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy combined with liver resection for concurrent peritoneal and hepatic metastases of gastrointestinal and gynecological primary tumors.
    Horvath P; Beckert S; Königsrainer A; Nadalin S; Königsrainer I
    J Visc Surg; 2019 Dec; 156(6):475-484. PubMed ID: 31324533
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer.
    Chayahara N; Tamura T; Yamamori M; Kadowaki Y; Okuno T; Miki I; Tsuda M; Nishisaki H; Maeda T; Inoue Y; Okumura K; Azuma T; Kasuga M; Sakaeda T; Hirai M
    Am J Clin Oncol; 2009 Feb; 32(1):56-60. PubMed ID: 19194126
    [TBL] [Abstract][Full Text] [Related]  

  • 83. 5-Fluorouracil and low-dose leucovorin in metastatic colorectal cancer: a pilot study.
    Fried G; Tsalik M; Stein M; Dale J; Haim N
    Cancer Chemother Pharmacol; 1995; 35(5):437-40. PubMed ID: 7850927
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil.
    Aschele C; Debernardis D; Bandelloni R; Cascinu S; Catalano V; Giordani P; Barni S; Turci D; Drudi G; Lonardi S; Gallo L; Maley F; Monfardini S
    Ann Oncol; 2002 Dec; 13(12):1882-92. PubMed ID: 12453856
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Carcinoma of the jejunum with multideposit peritoneal seeding, resection and intraperitoneal chemotherapy.
    Innis M; Sandiford N; Shenoy RK; Prussia PR; Zbar A
    West Indian Med J; 2005 Sep; 54(4):242-6. PubMed ID: 16312191
    [TBL] [Abstract][Full Text] [Related]  

  • 86. A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydroxyurea in metastatic colorectal carcinoma.
    O'Byrne KJ; Philip PA; Propper DJ; Braybrooke JP; Saunders MP; Bates NP; Taylor MA; Madigan D; Ganesan TS; Talbot DC; Harris AL
    Ann Oncol; 1999 Aug; 10(8):981-3. PubMed ID: 10509162
    [TBL] [Abstract][Full Text] [Related]  

  • 87. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
    Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen.
    André T; Louvet C; Raymond E; Tournigand C; de Gramont A
    Ann Oncol; 1998 Nov; 9(11):1251-3. PubMed ID: 9862058
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management.
    Pestieau SR; Sugarbaker PH
    Dis Colon Rectum; 2000 Oct; 43(10):1341-6; discussion 1347-8. PubMed ID: 11052509
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Cytoreductive surgery and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colonic origin: outcomes after 7 years' experience of a new centre for peritoneal surface malignancies.
    Bretcha-Boix P; Farré-Alegre J; Sureda M; Dussan C; Pérez Ruixo JJ; Brugarolas Masllorens A
    Clin Transl Oncol; 2010 Jun; 12(6):437-42. PubMed ID: 20534399
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Treatment of peritoneal carcinomatosis from colorectal cancer by cytoreductive surgery and hyperthermic perioperative intraperitoneal chemotherapy.
    Kecmanovic DM; Pavlov MJ; Ceranic MS; Sepetkovski AV; Kovacevic PA; Stamenkovic AB
    Eur J Surg Oncol; 2005 Mar; 31(2):147-52. PubMed ID: 15698730
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study. GISCAD, IOR and collaborating centers.
    Sobrero A; Zaniboni A; Frassineti GL; Aschele C; Guglielmi A; Giuliani R; Ravaioli A; Lanfranco C; Caroti C; Arnoldi E; Barni S; Gallo L; Pessi MA; Turci D; Cortesi E; Grossi F; Frontini L; Piazza E; Bruzzi P; Labianca R
    Ann Oncol; 2000 Nov; 11(11):1413-20. PubMed ID: 11142481
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients.
    Guglielmi A; Aschele C; Grossi F; Tixi L; Sobrero A
    Cytotechnology; 1996; 19(3):215-9. PubMed ID: 8862009
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Phase I/II study of twenty-four-hour infusion of irinotecan in combination with oral UFT plus leucovorin for metastatic colorectal cancer.
    Sadahiro S; Suzuki T; Maeda Y; Tanaka A; Ishikawa K; Makuuchi H; Murayama C
    Oncology; 2009; 76(5):338-41. PubMed ID: 19307740
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Clinical outcomes of complete cytoreduction with concurrent liver resection followed by hyperthermic intraperitoneal chemotherapy for synchronous peritoneal and liver metastatic colorectal cancer.
    Jeon Y; Park EJ; Lim JH; Baik SH
    World J Surg Oncol; 2019 Dec; 17(1):214. PubMed ID: 31829188
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
    Van Cutsem E; Hoff PM; Harper P; Bukowski RM; Cunningham D; Dufour P; Graeven U; Lokich J; Madajewicz S; Maroun JA; Marshall JL; Mitchell EP; Perez-Manga G; Rougier P; Schmiegel W; Schoelmerich J; Sobrero A; Schilsky RL
    Br J Cancer; 2004 Mar; 90(6):1190-7. PubMed ID: 15026800
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Immunotherapy for Peritoneal Carcinomatosis: Challenges and Prospective Outcomes.
    Ornella MSC; Badrinath N; Kim KA; Kim JH; Cho E; Hwang TH; Kim JJ
    Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190310
    [TBL] [Abstract][Full Text] [Related]  

  • 98. First experience with
    Larsen SG; Graf W; Mariathasan AB; Sørensen O; Spasojevic M; Goscinski MA; Selboe S; Lundstrøm N; Holtermann A; Revheim ME; Bruland ØS
    Front Med (Lausanne); 2023; 10():1070362. PubMed ID: 36936230
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Treatment for Peritoneal Metastasis of Patients With Colorectal Cancer.
    Kim YJ; Kim CH
    Ann Coloproctol; 2021 Dec; 37(6):425-433. PubMed ID: 34961304
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients.
    Larsen SG; Goscinski MA; Dueland S; Steigen SE; Hofsli E; Torgunrud A; Lund-Iversen M; Dagenborg VJ; Flatmark K; Sorbye H
    Br J Cancer; 2022 Mar; 126(5):726-735. PubMed ID: 34887523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.